仅用于工业应用或科学研究，不可用于人类或动物的临床诊断或治疗，非药用. Cetrelimab （JNJ 63723283; JNJ 3283） is a humanized IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 （Kd=1.72 nM, HEK293） to block the interaction of PD-1 with PD-L1 and PD-L2 （IC50s=111.7 ng/mL and 138.6 ng/mL, respectively）. Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo